Nektar Therapeutics (NKTR) Stock Price, Quote & News

Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing therapies that selectively modulate the immune system to treat autoimmune disorders in the United States and internationally. It develops NKTR-358, a regulatory T (Treg) cell stimulator designed to address the imbalance in the immune system underlying autoimmune disorders and chronic inflammatory conditions; PEG-CSF1, a polyethylene glycol (PEG) modified hematopoietic colony stimulating factor protein that is...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 482 5300

Fax: 415 339 5300

Website: www.nektar.com

Address:

455 Mission Bay Boulevard South, San Francisco, United States

george4it Feb. 4 at 12:34 AM

$NKTR Still holding and ready for the much awaited spike in price.

0 · Reply

JFais Feb. 3 at 11:29 PM

Only Tuesday and already some good discussions cooking in Chat: -How does $NKTR benefit from OX-40 failures, potential to take a slice of 1st line too? -More points made on $SLNO after my blog post, reminder it's trading at only 10x earning with 100% growth! -In non-bio channel $CEPT & other tokenization plays

0 · Reply

lovestockstwits Feb. 3 at 5:03 PM

$NKTR running

0 · Reply

BK217 Feb. 2 at 4:38 PM

$NKTR nice!

0 · Reply

masonat Feb. 2 at 3:19 PM

$NKTR OX40 competition is essentially dead.

0 · Reply

dayfornight99 Feb. 1 at 6:04 PM

$NKTR Is there a trial date yet? When is next status conference?

0 · Reply

calbucs Jan. 31 at 5:31 PM

$NKTR let’s get a few more days in of $3 plus and back over $50 awaiting results and launch to $70

0 · Reply

Zaksab Jan. 30 at 10:18 PM

$NKTR hunch is data drops next week

0 · Reply

george4it Jan. 30 at 8:55 PM

$NKTR Looks like it might be turning upwards, and on a big red day to boot.

0 · Reply

clarksonhockey Jan. 30 at 7:20 PM

$NKTR fire up the takeover machine!!

0 · Reply

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 15, 2026, 6:58 PM EST - 19 days ago

Nektar.io Introduces DIRT: Materials Management for the Construction Industry

Dec 17, 2025, 4:49 PM EST - 6 weeks ago

Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg

Dec 16, 2025, 1:29 PM EST - 7 weeks ago

Nektar Therapeutics (NKTR) Discusses Topline Results From REZOLVE-AA Phase 2b Study of rezpegaldesleukin in Alopecia Areata Transcript

Dec 16, 2025, 11:30 AM EST - 7 weeks ago

Nektar Alopecia Trial Misses Endpoint, Hits Significance After Patient Exclusion

Dec 15, 2025, 6:00 PM EST - 7 weeks ago

Nektar to Hold Conference Call to Discuss Topline Results from the 36-Week Induction Treatment Period for its REZOLVE-AA Phase 2b Study of Rezpegaldesleukin in Alopecia Areata on December 16, 2025

Nov 12, 2025, 10:59 AM EST - 2 months ago

Nektar Therapeutics: Balancing The Immune System To Potential Blockbuster Markets

Nov 12, 2025, 12:39 AM EST - 2 months ago

Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout

Nov 8, 2025, 5:45 PM EST - 3 months ago

New Data from REZOLVE-AD Study of Rezpegaldesleukin Presented in Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Nov 7, 2025, 4:26 PM EST - 3 months ago

Nektar Therapeutics (NKTR) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 4:15 PM EST - 3 months ago

Nektar Therapeutics Reports Third Quarter 2025 Financial Results

Oct 30, 2025, 6:00 PM EDT - 3 months ago

Nektar Therapeutics to Participate in the Jefferies Global Healthcare Conference in London

Oct 28, 2025, 6:00 PM EDT - 3 months ago

Nektar to Announce Financial Results for the Third Quarter on Thursday, November 6, 2025, After Close of U.S.-Based Financial Markets

Oct 28, 2025, 12:36 PM EDT - 3 months ago

San Francisco is making a comeback. So are these stocks from the City by the Bay

MAZE REAL

Oct 22, 2025, 8:00 AM EDT - 3 months ago

Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

Sep 18, 2025, 2:31 PM EDT - 4 months ago

Why Is Nektar Therapeutics Stock Trading Lower On Thursday?

Sep 18, 2025, 8:45 AM EDT - 4 months ago

Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025

Sep 9, 2025, 7:00 AM EDT - 5 months ago

Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025

Sep 4, 2025, 2:52 PM EDT - 5 months ago

What's Going On With Nektar Therapeutics Stock On Thursday?

Sep 3, 2025, 7:00 PM EDT - 5 months ago

Nektar Therapeutics to Participate in Two Investor Conferences in September

Aug 8, 2025, 7:48 PM EDT - 6 months ago

Nektar Therapeutics (NKTR) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:15 PM EDT - 6 months ago

Nektar Therapeutics Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 6:00 PM EDT - 6 months ago

Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After Close of U.S.-Based Financial Markets

Jul 29, 2025, 9:00 AM EDT - 6 months ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Severe-to-Very Severe Alopecia Areata

Jul 2, 2025, 4:15 PM EDT - 7 months ago

Nektar Therapeutics Announces Closing of $115 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Jul 1, 2025, 7:17 AM EDT - 7 months ago

Nektar Therapeutics Announces Pricing of $100 Million Public Offering

Jun 30, 2025, 4:02 PM EDT - 7 months ago

Nektar Therapeutics Announces Proposed Public Offering

Jun 27, 2025, 8:45 AM EDT - 7 months ago

Nektar Therapeutics Scores Big Phase 2b Win With Rezpeg

Jun 25, 2025, 1:42 PM EDT - 7 months ago

Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?

Jun 24, 2025, 1:20 PM EDT - 8 months ago

Nektar Therapeutics Is Up 150%: What's Happening With NKTR Stock?

Jun 24, 2025, 7:35 AM EDT - 8 months ago

Nektar Therapeutics' experimental eczema drug meets main goals of mid-stage trial

Jun 24, 2025, 7:30 AM EDT - 8 months ago

REZOLVE-AD Phase 2b Study of Rezpegaldesleukin Meets Primary and Key Secondary Endpoints in Patients with Moderate-to-Severe Atopic Dermatitis

Jun 23, 2025, 4:30 PM EDT - 8 months ago

Nektar to Announce Top-line Data from the 16-Week Induction Period in REZOLVE-AD Phase 2b Study of Rezpegaldesleukin, a Regulatory T-cell Proliferator, in Atopic Dermatitis on June 24, 2025

Jun 11, 2025, 3:13 PM EDT - 8 months ago

Nektar Therapeutics: 2 Data Readouts For REZPEG 2025 Could Establish Further POC

Jun 10, 2025, 5:26 PM EDT - 8 months ago

AMBROSIA & NEKTAR Introduces Premium High-End Organic Food from Greece with a Commitment to Purity and Provenance

May 13, 2025, 5:00 PM EDT - 9 months ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference

May 8, 2025, 10:08 PM EDT - 9 months ago

Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:15 PM EDT - 9 months ago

Nektar Therapeutics Reports First Quarter 2025 Financial Results

May 1, 2025, 6:00 PM EDT - 9 months ago

Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets

Mar 20, 2025, 6:00 PM EDT - 11 months ago

Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference

Mar 12, 2025, 8:00 PM EDT - 11 months ago

Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript

Mar 12, 2025, 4:15 PM EDT - 11 months ago

Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 5, 2025, 6:00 PM EST - 11 months ago

Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets

Feb 26, 2025, 7:00 AM EST - 1 year ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata

Feb 24, 2025, 7:00 AM EST - 1 year ago

Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus

Feb 24, 2025, 7:00 AM EST - 1 year ago

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

Feb 10, 2025, 7:00 AM EST - 1 year ago

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

Jan 10, 2025, 7:00 AM EST - 1 year ago

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

$Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting$

Dec 7, 2024, 12:00 PM EST - 1 year ago

Nektar Therapeutics Announces NKTR-255 Following CD19-directed CAR-T Therapy Enhanced Complete Response Rates in Patients with Relapsed or Refractory Large B-cell Lymphoma at the 66th Annual ASH Meeting

george4it Feb. 4 at 12:34 AM

$NKTR Still holding and ready for the much awaited spike in price.

0 · Reply

JFais Feb. 3 at 11:29 PM

0 · Reply

lovestockstwits Feb. 3 at 5:03 PM

$NKTR running

0 · Reply

BK217 Feb. 2 at 4:38 PM

$NKTR nice!

0 · Reply

masonat Feb. 2 at 3:19 PM

$NKTR OX40 competition is essentially dead.

0 · Reply

dayfornight99 Feb. 1 at 6:04 PM

$NKTR Is there a trial date yet? When is next status conference?

0 · Reply

calbucs Jan. 31 at 5:31 PM

$NKTR let’s get a few more days in of $3 plus and back over $50 awaiting results and launch to $70

0 · Reply

Zaksab Jan. 30 at 10:18 PM

$NKTR hunch is data drops next week

0 · Reply

george4it Jan. 30 at 8:55 PM

$NKTR Looks like it might be turning upwards, and on a big red day to boot.

0 · Reply

clarksonhockey Jan. 30 at 7:20 PM

$NKTR fire up the takeover machine!!

0 · Reply

topstockalerts Jan. 30 at 7:12 PM

$NKTR Momentum plays are lighting up again 🔥. Buyers are chasing strength. This environment rewards trend followers.

0 · Reply

ignoreo Jan. 30 at 7:01 PM

$NKTR a 21m mcap increase, just 10b more to go

0 · Reply

george4it Jan. 30 at 5:16 PM

$NKTR as expected, nice bounce, again.

1 · Reply

george4it Jan. 30 at 5:08 PM

$NKTR Just wondering if this is a holder of shares selling their position or just shorts applying pressure.

0 · Reply

PhoenixHedge Jan. 30 at 3:33 PM

$AMGN $NKTR $SNY how’s that working out?

1 · Reply

masonat Jan. 30 at 1:43 PM

$NKTR First the $SNY amlitelimab news, now $AMGN is walking away from rocatinlimab. Atopic derm market is wide open outside of Dupixent and Dupi me toos.

0 · Reply

BK217 Jan. 29 at 9:05 PM

$NKTR just taking the boat out now in Cabo. Life is good

0 · Reply

Thedeuceze Jan. 29 at 5:01 PM

$NKTR His will dump

1 · Reply

george4it Jan. 28 at 11:32 PM

$NKTR The more they try to push it lower, the more convinced I am we are moving closer to a spike back to the 60’s and beyond. LLY still playing games. Jmo of course.

1 · Reply

Traidn Jan. 28 at 6:22 PM

$NKTR 🚨🚨🚨 https://www.cosmopolitan.com/uk/body/health/a69026132/nipah-virus/

1 · Reply

BK217 Jan. 28 at 1:28 PM

$NKTR short interest continues to increase, but not by as much as the last report. DTC around 5-6 What do they purport to know that you and I do not?

1 · Reply

BK217 Jan. 27 at 11:03 PM

$NKTR

2 · Reply

Market Cap	759.37M
Revenue (ttm)	98.43M
Net Income (ttm)	-118.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-120.86%
Debt to Equity Ratio	0.00

Volume	494,100
Avg Vol	808,920
Day's Range	N/A - N/A
Shares Out	20.34M
Stochastic %K	86%
Beta	1.31
Analysts	Strong Sell
Price Target	$114.43